In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dendreon rockets on unexpected high growth 4Q Provenge sales

This article was originally published in Scrip

Executive Summary

Dendreon, which took a beating during much of 2011, rang in 2012 with unexpectedly high fourth-quarter sales of its prostate cancer immunotherapy Provenge (sipuleucel-T) – nearly tripling figures from a year earlier – which had investors reveling in the good news.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC015804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel